Abstract: The present invention relates to compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers, prodrugs, hydrates and or derivatives thereof. The Pharmaceutical composition comprises an effective amount of compounds of formula I, formula II, formula III, formula IV, Formula V, formula VI or formula VII and the methods of using the composition for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermaladministration, spray, injection or other known formulation in the art.
| # | Name | Date |
|---|---|---|
| 1 | 202247006765.pdf | 2022-02-08 |
| 2 | 202247006765-STATEMENT OF UNDERTAKING (FORM 3) [08-02-2022(online)].pdf | 2022-02-08 |
| 3 | 202247006765-PROOF OF RIGHT [08-02-2022(online)].pdf | 2022-02-08 |
| 4 | 202247006765-PRIORITY DOCUMENTS [08-02-2022(online)].pdf | 2022-02-08 |
| 5 | 202247006765-POWER OF AUTHORITY [08-02-2022(online)].pdf | 2022-02-08 |
| 6 | 202247006765-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [08-02-2022(online)].pdf | 2022-02-08 |
| 7 | 202247006765-FORM FOR SMALL ENTITY(FORM-28) [08-02-2022(online)].pdf | 2022-02-08 |
| 8 | 202247006765-FORM 1 [08-02-2022(online)].pdf | 2022-02-08 |
| 9 | 202247006765-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [08-02-2022(online)].pdf | 2022-02-08 |
| 10 | 202247006765-DECLARATION OF INVENTORSHIP (FORM 5) [08-02-2022(online)].pdf | 2022-02-08 |
| 11 | 202247006765-COMPLETE SPECIFICATION [08-02-2022(online)].pdf | 2022-02-08 |
| 12 | 202247006765-Correspondence_Form-1 And POA_24-02-2022.pdf | 2022-02-24 |
| 13 | 202247006765-FORM 3 [22-05-2023(online)].pdf | 2023-05-22 |
| 14 | 202247006765-FORM 18 [07-06-2023(online)].pdf | 2023-06-07 |
| 15 | 202247006765-FER.pdf | 2024-04-04 |
| 1 | 202247006765E_28-03-2024.pdf |